We're unable to sign you in at this time. Please try again in a few minutes.
We were able to sign you in, but your subscription(s) could not be found. Please try again in a few minutes.
There may be a problem with your account. Please contact the AMA Service Center to resolve this issue.
Contact the AMA Service Center:
Telephone: 1 (800) 262-2350 or 1 (312) 670-7827  *   Email: subscriptions@jamanetwork.com
Error Message ......
Comment & Response |

Testosterone as the Missing Link Between Pesticides, Alzheimer Disease, and Parkinson Disease

Ralph Martins, AO, PhD1; Malcolm Carruthers, MD, FRCPath1
[+] Author Affiliations
1McCusker Alzheimer’s Research Foundation, Edith Cowan University, Nedlands, Australia
JAMA Neurol. 2014;71(9):1189-1190. doi:10.1001/jamaneurol.2014.795.
Text Size: A A A
Published online


To the Editor The article by Richardson et al1 reporting the elevated levels of dichlorodiphenyldichloroethylene (DDE) in patients with Alzheimer disease raises the strong possibility that the missing link is the antitestosterone effect of many pesticides causing increased β-amyloid production.

Pesticides, including dichlorodiphenyltrichloroethane (DDT), and particularly their breakdown product DDE have been linked with both Alzheimer2 and Parkinson diseases.3 The exact mechanism of action has been intensely researched, with some favoring a direct action of the different toxins on the neurones and others an indirect action via their ability to induce oxidative stress, mitochondrial dysfunction, and α-synuclein fibrillization. However, there is general agreement that exposure to multiple pesticides, genetic factors, and traumatic brain injury can also predispose an individual to getting 1 or both of these conditions.


Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

First Page Preview

View Large
First page PDF preview





September 1, 2014
Jason R. Richardson, MS, PhD
1Rutgers Robert Wood Johnson Medical School, Environmental and Occupational Health Sciences Institute, Piscataway, New Jersey
JAMA Neurol. 2014;71(9):1190. doi:10.1001/jamaneurol.2014.1814.
Also Meets CME requirements for:
Browse CME for all U.S. States
Accreditation Information
The American Medical Association is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. The AMA designates this journal-based CME activity for a maximum of 1 AMA PRA Category 1 CreditTM per course. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Physicians who complete the CME course and score at least 80% correct on the quiz are eligible for AMA PRA Category 1 CreditTM.
Note: You must get at least of the answers correct to pass this quiz.
Please click the checkbox indicating that you have read the full article in order to submit your answers.
Your answers have been saved for later.
You have not filled in all the answers to complete this quiz
The following questions were not answered:
Sorry, you have unsuccessfully completed this CME quiz with a score of
The following questions were not answered correctly:
Commitment to Change (optional):
Indicate what change(s) you will implement in your practice, if any, based on this CME course.
Your quiz results:
The filled radio buttons indicate your responses. The preferred responses are highlighted
For CME Course: A Proposed Model for Initial Assessment and Management of Acute Heart Failure Syndromes
Indicate what changes(s) you will implement in your practice, if any, based on this CME course.


Some tools below are only available to our subscribers or users with an online account.

0 Citations

Sign in

Purchase Options

• Buy this article
• Subscribe to the journal
• Rent this article ?

Related Content

Customize your page view by dragging & repositioning the boxes below.

See Also...